Arca
Skip to content

BLA 761082: Complete Response Letter

A complete response letter is FDA's decision not to approve an application as submitted. See BLA 761082's history or Kashiv BioSciences, LLC's company page.

On Aug 2, 2021, FDA declined to approve BLA 761082 (BLA 761082) from Kashiv BioSciences, LLC in its present form, citing facility inspections, product quality. The application was later approved.

  • Letter date: Aug 2, 2021
  • Application: BLA 761082
  • Since then: Approved

What FDA Cited

FDA's own section headings in the letter; each finds other letters citing it

Facility inspectionsProduct quality

The Letter

Text from openFDA

1. Aninspection of the Kashiv Biosciences LLC DS manufacture facility (FEI 3011289655), Chicago, Illinois, is required before this application can be approved as the FDA must assess the ability of that facility to conduct the listed manufacturing operations in...… openFDA did not return the full text just now. Open it in the letter search.

Other Letters on This Application

Kashiv BioSciences, LLC's Other Letters

Newest first
  • TPI-120Aug 11, 2021 · BLA 761084 · later approved

Record

Company
Kashiv BioSciences, LLC
Application
BLA 761082
Status in openFDA
Approved
Review division
Division of Nonmalignant Hematology

FDA has published complete response letters since 2025, with some redactions. The status is openFDA's: whether the application was eventually approved. openFDA complete response letters

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.